Literature DB >> 17563394

Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Amy C Degnim1, Daniel W Visscher, Hal K Berman, Marlene H Frost, Thomas A Sellers, Robert A Vierkant, Shaun D Maloney, V Shane Pankratz, Piet C de Groen, Wilma L Lingle, Karthik Ghosh, Lois Penheiter, Thea Tlsty, L Joseph Melton, Carol A Reynolds, Lynn C Hartmann.   

Abstract

PURPOSE: Atypical hyperplasia is a well-recognized risk factor for breast cancer, conveying an approximately four-fold increased risk. Data regarding long-term absolute risk and factors for risk stratification are needed. PATIENTS AND METHODS: Women with atypical hyperplasia in the Mayo Benign Breast Disease Cohort were identified through pathology review. Subsequent breast cancers were identified via medical records and a questionnaire. Relative risks (RRs) were estimated using standardized incidence ratios, comparing the observed number of breast cancers with those expected based on Iowa Surveillance, Epidemiology, and End Results (SEER) data. Age, histologic factors, and family history were evaluated as risk modifiers. Plots of cumulative breast cancer incidence provided estimates of risk over time.
RESULTS: With mean follow-up of 13.7 years, 66 breast cancers (19.9%) occurred among 331 women with atypia. RR of breast cancer with atypia was 3.88 (95% CI, 3.00 to 4.94). Marked elevations in risk were seen with multifocal atypia (eg, three or more foci with calcifications [RR, 10.35; 95% CI, 6.13 to 16.4]). RR was higher for younger women (< 45; RR, 6.76; 95% CI, 3.24 to 12.4). Risk was similar for atypical ductal and atypical lobular hyperplasia, and family history added no significant risk. Breast cancer risk remained elevated over 20 years, and the cumulative incidence approached 35% at 30 years.
CONCLUSION: Among women with atypical hyperplasia, multiple foci of atypia and the presence of histologic calcifications may indicate "very high risk" status (> 50% risk at 20 years). A positive family history does not further increase risk in women with atypia.

Entities:  

Mesh:

Year:  2007        PMID: 17563394     DOI: 10.1200/JCO.2006.09.0217

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  73 in total

Review 1.  Clinical and epidemiological issues in mammographic density.

Authors:  Valentina Assi; Jane Warwick; Jack Cuzick; Stephen W Duffy
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

3.  Use of clinical history affects accuracy of interpretive performance of screening mammography.

Authors:  Patricia A Carney; Andrea J Cook; Diana L Miglioretti; Stephen A Feig; Erin Aiello Bowles; Berta M Geller; Karla Kerlikowske; Mark Kettler; Tracy Onega; Joann G Elmore
Journal:  J Clin Epidemiol       Date:  2011-10-15       Impact factor: 6.437

Review 4.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

Review 5.  Suitable trial designs and cohorts for preventive breast cancer agents.

Authors:  Kathrin Strasser-Weippl; Paul E Goss
Journal:  Nat Rev Clin Oncol       Date:  2013-10-08       Impact factor: 66.675

6.  Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Authors:  Meghna S Trivedi; Austin M Coe; Alejandro Vanegas; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

7.  Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia.

Authors:  Rhiana S Menen; Nivetha Ganesan; Therese Bevers; Jun Ying; Robin Coyne; Deanna Lane; Constance Albarracin; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2016-08-29       Impact factor: 5.344

8.  Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.

Authors:  Marta Santisteban; Carol Reynolds; Emily G Barr Fritcher; Marlene H Frost; Robert A Vierkant; Stephanie S Anderson; Amy C Degnim; Daniel W Visscher; V Shane Pankratz; Lynn C Hartmann
Journal:  Breast Cancer Res Treat       Date:  2009-09-23       Impact factor: 4.872

9.  A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.

Authors:  Geoffrey C Kabat; Joan G Jones; Neal Olson; Abdissa Negassa; Catherine Duggan; Mindy Ginsberg; Rita A Kandel; Andrew G Glass; Thomas E Rohan
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

10.  Assessment of the accuracy of the Gail model in women with atypical hyperplasia.

Authors:  V Shane Pankratz; Lynn C Hartmann; Amy C Degnim; Robert A Vierkant; Karthik Ghosh; Celine M Vachon; Marlene H Frost; Shaun D Maloney; Carol Reynolds; Judy C Boughey
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.